Conditions: Chronic Plaque Type Psoriasis
Keywords: chronic plaque type psoriasis, secukinumab, ustekinumab, inflammatory skin disease, scaling
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 676
Healthy volunteers: no

Brief summary:
This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis

Detailed description:

Arms:
arm 1: patients received AIN457 (secukinumab) 300 mg (two secukinumab 150 mg injections) s.c. (subcutaneously) once every week at weeks 0, 1,2,3, followed by monthly dosing starting at week 4 to week 48 inclusive arm 2: patients received ustekinumab 45/90 mg (weight depended, according to label) s.c. (subcutaneously) and/or placebo secukinumab injections once every week at weeks 0,1,2, and 3 followed by monthly dosing starting at week 4 to week 48 inclusive

Interventions: intervention 1: AIN457 300 mg intervention 2: ustekinumab 45/90 mg intervention 3: placebo secukinumab
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: Placebo

Protocol document: